VIDEO: STRIDE study examines TYK2 inhibitor for plaque psoriasis
Click Here to Manage Email Alerts
In this Healio exclusive video, Steven R. Feldman, MD, PhD, discussed psoriasis research from the phase 2 STRIDE study presented at the American Academy of Dermatology Annual Meeting.
Feldman, professor of dermatology, pathology and social sciences and health policy at Wake Forest University School of Medicine, discussed the study, which looked into the efficacy and safety of the highly selective oral tyrosine kinase 2 (TYK2) inhibitor ESK-001 (Alumis) in the treatment of mild to severe plaque psoriasis.
If ESK-001 is more specific for TYK2 than other options, such as deucravacitinib [Sotyktu, Bristol Myers Squibb], it may be able to “squeeze a little more efficacy out,” Feldman told Healio.
“But I’m worried that with more interferon blockade, we’re going to have even more of a virus signal that we have already with the 1 in 100 zoster rate that we have with deucravacitinib,” Feldman said.
Collapse
Read more about
Click Here to Manage Email Alerts